Incyte (WBO:INCY) Beta: N/A (As of Jun. 25, 2026)


WBO:INCY Incyte Corp WBO:INCY
88 GF Score
Price €70.36
GF Value €64.47
! 3 Warning Signs
View Full Analysis

What is Incyte Beta?

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Incyte's Beta is Not available.


Incyte  (WBO:INCY) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Incyte Beta Related Terms


Incyte Beta Historical Data

* Premium members only.

The historical data trend for Incyte's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Beta Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.15 0.01 0.00 0.00

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WBO:INCY vs MRNA, ROIV, INSM: Beta Comparison

For the Biotechnology subindustry, Incyte's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Incyte Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Incyte's Beta distribution charts can be found below:

* The bar in red indicates where Incyte's Beta falls into.


WBO:INCY
88GF Score
Incyte Corp WBO:INCY
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Is Incyte (WBO:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of €70.36 is trading 9.1% above its estimated GF Value™ of €64.47.

Key valuation signals for WBO:INCY:

  • Beta: N/A
  • GF Value™: €64.47 vs. price of €70.36 (9.1% above fair value)
  • GF Score™: 88/100 with 3 warning signs

No single metric tells the full story. See the WBO:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
88GF Score

Get the complete analysis for WBO:INCY

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.36
Price
€64.47
GF Value